Amphastar Pharmaceuticals, Inc. AMPH

AMPH Company Overview

Amphastar Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients (APIs). The company operates primarily within the pharmaceutical and biotechnology industries, with a concentration on technically challenging drug products that often involve complex formulations, sterile manufacturing, or device-based delivery systems. Amphastar generates revenue through sales of generic pharmaceuticals, branded products, insulin APIs, and contract manufacturing activities.

The company’s primary business lines include injectable drugs used in hospital and emergency settings, intranasal products, inhalation therapies, and diabetes-related pharmaceutical ingredients. Key revenue drivers have included products such as glucagon emergency kits, naloxone products, enoxaparin, and Primatene MIST. Amphastar serves hospitals, retail pharmacies, wholesalers, group purchasing organizations, and government healthcare channels primarily in the United States, while also maintaining international commercial and manufacturing operations. The company traces its origins to 1996 and expanded through internal development, manufacturing integration, and acquisitions, including the purchase of BAQSIMI from Eli Lilly and Company in 2023, which broadened its branded diabetes emergency treatment portfolio.